Impact of risk minimisation in patients treated with rosiglitazone-containing products

First published 26/01/2011

Last updated 02/07/2024

EU PAS number:

EUPAS1777

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

Protocol_ENcEPP_Submitted

English (200.49 KB - PDF)View document

Study results

Rosiglitazone_executive_summary_for_ENCePP

English (12.41 KB - PDF)View document

Study report

Other information

Study, other information

Data access procedures

English (10.31 KB - PDF)View document

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

Conflict of interest statement

English (7.44 KB - PDF)View document

Composition of steering group and observers

Steering Committee statement

English (7.44 KB - PDF)View document

Signed code of conduct

2011-0004-cocdecl 14.01.2011

English (32.03 KB - PDF)View document

Signed code of conduct checklist

2011-0004-CoCcklist 21.01.1011

English (183.17 KB - PDF)View document

Signed checklist for study protocols

2011-0004-cklistmeth14.01.2011

English (165.32 KB - PDF)View document

Impact of risk minimisation in patients treated with rosiglitazone-containing products

Secondary tabs

Share this page